血小板グリコプロテインIIb/IIIaアンタゴニスト. 薬理学と臨床使用に関する重要な問題は何ですか?

R M Scarborough¹, N S Kleiman, D R Phillips

¹COR Therapeutics, Inc, South San Francisco, CA, USA. scarborough@corr.com

Circulation

|July 27, 1999

まとめ

血小板グリコプロテイン (GP) IIb/IIIaアンタゴニストは,急性冠動脈症候群の治療に不可欠です. よりよい患者の治療結果のために,薬理学と臨床使用を最適化するためにさらなる研究が必要である.

科学分野:

心血管医学は,心臓血管医学である.
薬理学薬理学とは
血液学ヘマトロジ

背景:

血小板糖タンパク質 (GP) IIb/IIIa複合体は,血栓形成を阻害する重要な標的である.
GP IIb/IIIaアンタゴニストは,急性冠動脈症候群の治療において有望であることが示されています.

研究の目的:

GPIIb/IIIaアンタゴニストに関する未解決の問題を検討する.
薬理学,臨床的有用性,および将来の治療の可能性を調査する.

主な方法:

GPIIb/IIIaアンタゴニストに関する既存の文献のレビュー.
薬理学的性質の分析:親和性,可逆性,特異性など.
臨床アプリケーションの課題とモニタリングの議論.

主要な成果:

いくつかのGP IIb/IIIaアンタゴニストは,臨床的有用性を示しています.
未解決の問題は,受容体の可用性,ネオエピトープ誘発性血栓縮症,モニタリング方法などである.
経口抗剤の治療指標については,さらなる評価が必要である.

結論:

GP IIb/IIIaアンタゴニスト治療の最適化には,薬理学的および臨床的な不確実性に対処する必要があります.
将来の研究は,この薬剤クラスのより広範な臨床応用を決定します.

さらに関連する動画

06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

08:58

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Published on: July 5, 2018

関連する概念動画

01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

01:30

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

関連する実験動画